Here are four updates on GI companies from the past week.
Takeda's shareholders are urging the company to put its $62 billion acquisition of Shire to a vote.
Lumendi received FDA 510(k) clearance for the DiLumen Is Endolumenal Interventional Scissors.
Motus GI enrolled the first patient into its reliable endoscopic diagnosis utilizing cleansing enhancement, or REDUCE, study that'll test the ability of the Pure-Vu System to properly prepare bowels for a diagnostic colonoscopy procedure.
Prescient Surgical's novel wound retractor CleanCision is associated with reduced bacterial contamination in colorectal surgery.